{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-019217","form_type":"8-K","ticker":"MLTX","cik":"0001821586","company_name":"MoonLake Immunotherapeutics","filed_at":"2022-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.519120+00:00","generated_at":"2026-06-26T08:18:28.312315+00:00","sec_items":["1.01","2.01","9.01","3.02","3.03","5.01","5.02","5.03","5.05","5.06","7.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"MoonLake Immunotherapeutics (fka Helix Acquisition) closes business combination, lists on Nasdaq","bullets":["Closed business combination Apr 5, 2022; Helix acquired MoonLake AG, renamed MoonLake Immunotherapeutics (MLTX).","Issued 36.9M Class A shares and 15.8M Class C shares; PIPE investors subscribed 11.7M Class A shares at $10.00 each, grossing ~$116M.","Existing MoonLake AG shareholders received 18.5M Class A and 15.8M Class C shares; lock-up periods of 6 to 12 months apply.","Helix contributed $134.6M to MoonLake AG, including $15M loan repayment to Cormorant Asset Management.","New equity incentive plan adopted; initial grants of 45,000 options per non-management director; indemnification agreements executed."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-019217","json":"https://secwatch.observer/filing/0001213900-22-019217.json","markdown":"https://secwatch.observer/filing/0001213900-22-019217.md","text":"https://secwatch.observer/filing/0001213900-22-019217.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/0001213900-22-019217-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/ea158227-8k_moonlake.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T08:18:28.312315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"394de9394d","claim":"Will Lewis resigned as Director at MoonLake Immunotherapeutics.","evidence_excerpt":"In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/0001213900-22-019217-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"857649b1e6","claim":"John Schmid resigned as Director at MoonLake Immunotherapeutics.","evidence_excerpt":"In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/0001213900-22-019217-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"8956f1eb3f","claim":"Dr. Andrew J. Phillips resigned as Officer at MoonLake Immunotherapeutics.","evidence_excerpt":"In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/0001213900-22-019217-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Officer"}],"fact_type":"executive_change"},{"claim_id":"910ee9689e","claim":"Dr. Nancy Chang resigned as Director at MoonLake Immunotherapeutics.","evidence_excerpt":"In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/0001213900-22-019217-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d7c0570510","claim":"Bihua Chen resigned as Officer at MoonLake Immunotherapeutics.","evidence_excerpt":"In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/0001213900-22-019217-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Officer"}],"fact_type":"executive_change"},{"claim_id":"ee0588cd23","claim":"Bihua Chen resigned as Director at MoonLake Immunotherapeutics.","evidence_excerpt":"In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821586/000121390022019217/0001213900-22-019217-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}